Yes, epigenetic clocks are the most scientifically validated method available. These tests analyze DNA methylation patterns — chemical markers that accumulate on your DNA over time — to estimate how fast your body is actually ageing at a cellular level. According to research published in Nature Aging, leading epigenetic clocks can estimate age with a median accuracy of within 3–5 years, and have been shown in multiple studies to predict future disease risk and mortality, not just chronological age. It's worth noting these remain investigational biomarkers rather than FDA-cleared diagnostic tools, which is why they're used at Elysium as one input within a broader diagnostic picture, not a standalone verdict.

There's early clinical evidence for this. A 2022 study published in GeroScience tracked 10 specific protein biomarkers before and after therapeutic plasma exchange, finding reduced cellular senescence and lower DNA damage in blood cells following treatment. This is promising, biomarker-level evidence — not yet proof that plasma exchange extends lifespan — but it does support the biological rationale behind using apheresis to influence ageing-related blood factors. At Elysium, this is one of several tools used within AION RESET, applied where diagnostics indicate it's appropriate.

There is at least one rigorous clinical trial suggesting reversal is possible, not just theoretical. The TRIIM trial, published in Aging Cell (2019), followed nine healthy men aged 51–65 over one year of a thymus-regeneration protocol, and found their epigenetic age had decreased by an average of 1.5 years relative to baseline, measured consistently across multiple independent epigenetic clocks. It's important to note this was a small pilot study, not a large-scale trial, and the intervention used isn't part of Elysium's protocol. But it does represent real, peer-reviewed evidence that biological age is not a one-directional process — under the right conditions, it can move in reverse, at least at the biomarker level.

Mitochondrial decline is driven primarily by the gradual accumulation of damage to mitochondrial DNA (mtDNA). According to a review published in PMC, mtDNA has a significantly higher mutation rate than the DNA in a cell's nucleus, and repairs itself less efficiently — so damage accumulates over decades. This leads to increased production of reactive oxygen species (free radicals), which further damages mitochondria and the surrounding cell, creating a self-reinforcing cycle. Because mitochondria are your cells' primary energy source, this decline is directly linked to reduced energy production, slower recovery, and increased vulnerability to age-related disease, which is why mitochondrial support is a core focus of AION RESET.

Yes, "inflammaging" is a well-established term in ageing research, describing the chronic, low-grade inflammation that tends to increase with age even in the absence of acute infection or illness. According to research published in PMC, this persistent inflammatory state is now recognised as one of the central mechanisms connecting many of the other biological hallmarks of ageing, meaning it doesn't just accompany ageing, it actively drives dysfunction in other systems over time. This is why chronic inflammation is treated as a primary target within AION RESET, rather than an isolated symptom to manage separately.